Total ADME Support for Nucleic Acids

Nucleic acid therapeutics require radiolabeled ADME studies for regulatory approval, but traditional radiolabeling methods face significant challenges including high costs, low yields, and unstable compounds. In this on-demand webinar, experts from BioAgilytix and Sekisui Medical present FT-labelling technology—a novel solution that overcomes these limitations. Learn how this innovative approach enables comprehensive pharmacokinetic evaluation, accurate metabolite tracking, and stable radiolabeled compounds to support your nucleic acid drug development programs.